Rates of kidney stones are increasing globally, especially in the United States. A study led by the Mass General Brigham investigators found an association between the use of sodium-glucose contratransporter 2 (SGLT2) inhibitors and a lower risk of kidney stones. The data from three nationwide databases of patients with type 2 diabetes showed that those taking SGLT2 inhibitors had a 30% lower risk of developing kidney stones than those taking other classes of diabetes medications. These findings could help guide clinical decision-making for patients with diabetes at risk of developing kidney stones. The study was published in JAMA Internal Medicine.
Source link
SGLT2 inhibitors linked to lower risk of kidney stones in patients with type 2 diabetes
